Pharmaceutical Compositions of a HER2/neu Antibody and Use of the Same
AssigneeMacroGenics, Inc.
InventorsDavid Lee Farb, Yan Zhou, Krishnan Sampathkumar
Life of this patent
Estimating the term…
Abstract
The present invention is directed in part to pharmaceutical compositions for storage and administration comprising a) a HER2/neu antibody (“margetuximab”), b) buffering agents, and c) stabilizers, wherein said margetuximab is stable. The invention in part provides, containers and kits comprising such pharmaceutical compositions. The invention is directed in part to the use of such pharmaceutical compositions, containers, and kits containing margetuximab in the treatment of HER2/neu-positive cancer (i.e., a cancer that expresses HER2), including breast cancer or gastric cancer or GEJ cancer.
Claims31
1-68. (canceled)
A pharmaceutical composition comprising, a concentration of margetuximab from about 20 mg/mL to about 100 mg/mL, a sodium phosphate monohydrate buffer, a sodium phosphate dibasic heptahydrate buffer, sodium chloride, L-arginine hydrochloride and sucrose as stabilizers, polysorbate 80 (“PS80”) and water, wherein the margetuximab is stable.
Dependencies are inferred from the claim text.